Business News

Biogen Partners to Develop Gene Therapies for Hemophilia

Biogen Idec is teaming up with Fondazione Telethon and Ospedale San Raffaele to develop gene therapies for hemophilia A and B. The worldwide collaboration will combine San Raffaele-Telethon Institute for Gene Therapy’s (TIGET) extensive expertise in creating new gene therapy strategies and developing them from bench to bedside with Biogen’s …

Read More »

Quest Diagnostics and CDC Partner to Improve Hepatitis Diagnosis and Treatment

Quest Diagnostics is collaborating with the Centers for Disease Control and Prevention (CDC) to identify trends in screening, diagnosis and treatment of four strains of viral hepatitis in the US. Quest Diagnostics will provide CDC researchers with analytics and access to its national database of de-identified clinical testing hepatitis data. …

Read More »

Syncona and UCL Business Form Cancer Immunotherapy Company Autolus

Backed with roughly $45.5 million, Investment company Syncona and UCL Business, the wholly-owned technology transfer company of University College London, have launched the latest CAR T upstart, Autolus Limited. According to the companies, Autolus is a biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies for …

Read More »

European Health Regulators to Review AstraZeneca’s Investigational Gout Drug

The European Medicines Agency (EMA) has accepted AstraZeneca’s marketing authorization application for its investigational gout drug, which the company acquired through its acquisition of Ardea Biosciences. AstraZeneca said that the EMA accepted its application for lesinurad 200mg tablets for the chronic treatment of hyperuricaemia in gout patients. Lesinurad is a …

Read More »

Kite Pharma and Tel Aviv Sourasky Medical Center Expand Agreement for Novel CAR T Cell Therapy Products

Today, Kite Pharma, Inc. announced that it has expanded its immuno-oncology partnership with Tel Aviv Sourasky Medical Center. The US-based biopharmaceutical company expanded its agreement with the Israeli university to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite’s most advanced programs in cancer immunotherapy. …

Read More »

Roche Expands its Rare Disease Portfolio with Trophos Acquisition

Swiss drugmaker Roche has signed an agreement to acquire privately-held Trophos for up to $545 million. The acquisition will provide Roche with Trophos’ candidate for the rare and debilitating spinal muscular atrophy (SMA). Trophos’ proprietary screening platform generated olesoxime (TRO19622), which is in mid-stage development for SMA. SMA is a …

Read More »